HZNP - Amgen-Horizon Therapeutics $28B Acquisition: Federal Trade Commission Gives Green Signal | Benzinga
The U.S. Federal Trade Commission (FTC) has approved drug manufacturer Amgen Inc (NASDAQ: AMGN) to proceed with its $27.8 billion acquisition of Horizon Therapeutics Plc (NASDAQ: HZNP).
This decision reverses the FTC's earlier objections to the deal. In May, the FTC filed a lawsuit to block the transaction but later suspended its opposition in late August.
This suspension allowed the FTC to explore the possibility of settling the case.
Amgen's move to acquire Horizon in December 2022 aimed to ...